Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
J Urol ; 178(5): 2155-9, 2007 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-17870119

RESUMO

PURPOSE: We review our experience with renal manifestations in pediatric patients with the tuberous sclerosis complex, and offer recommendations for urological counseling, followup and treatment of these patients. MATERIALS AND METHODS: We reviewed clinical notes on 41 patients with the tuberous sclerosis complex followed at our institution from childhood. Patient data were gathered in a database focusing on renal involvement. The latter was assessed by periodic clinical evaluations and ultrasound. The risk of renal involvement was evaluated in relation to patient age, genotypic pattern and number of extrarenal manifestations. RESULTS: Overall, 15 patients (36.6%) had renal involvement. The latter increased with age and was more common in cases with TSC2 genotypic pattern or multiple extrarenal manifestations. Angiomyolipomas were the most common lesions (11 patients), followed by renal cysts (2) and polycystic kidney disease (2). Cystic lesions were the most common in patients younger than 16 years. Renal failure developed in the 2 patients with polycystic kidney disease by the 2nd decade of life. Overall, treatment was required in 2 cases of symptomatic angiomyolipoma. Both patients were female, and had multiple extrarenal manifestations and bilateral renal involvement. One patient underwent open surgery at age 21.3 years and 1 underwent radiological embolization at age 23.4 years. CONCLUSIONS: Pediatric patients with the tuberous sclerosis complex should undergo urological evaluation and followup. Although most of the lesions remain silent during childhood, the incidence of renal involvement increases with age. The need for treatment is highest in females with multiple extrarenal manifestations and bilateral renal involvement.


Assuntos
Aconselhamento/métodos , Nefropatias/terapia , Esclerose Tuberosa/terapia , Distribuição por Idade , Criança , Pré-Escolar , Gerenciamento Clínico , Feminino , Seguimentos , Humanos , Incidência , Lactente , Recém-Nascido , Itália/epidemiologia , Nefropatias/diagnóstico , Nefropatias/epidemiologia , Imageamento por Ressonância Magnética , Masculino , Prognóstico , Estudos Retrospectivos , Distribuição por Sexo , Fatores de Tempo , Esclerose Tuberosa/diagnóstico , Esclerose Tuberosa/epidemiologia , Urografia
2.
Neurogenetics ; 8(1): 57-60, 2007 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-17031678

RESUMO

Pelizaeus-Merzbacher disease (PMD) and Pelizaeus-Merzbacher-like disease (PMLD) are hypomyelinating disorders of the central nervous system with a very similar phenotype. PMD is an X-linked disorder caused by mutations in PLP1. PMLD is an autosomal recessive condition caused by mutations in GJA12. We report a 5-year-old girl with a complex neurological syndrome and severe hypomyelination on brain magnetic resonance imaging. She harbored a homozygous 34-bp deletion in the coding region of GJA12. There are no distinctive features for the differential diagnosis of PMD/PMLD. GJA12 should be analyzed in all patients without PLP1 mutations but should also be considered the initial genetic test in women and in patients with consanguineous parents.


Assuntos
Conexinas/genética , Doença de Pelizaeus-Merzbacher/genética , Deleção de Sequência , Sequência de Bases , Pré-Escolar , DNA/química , DNA/genética , Primers do DNA , Feminino , Genes Recessivos , Humanos , Dados de Sequência Molecular , Conformação de Ácido Nucleico
3.
Pediatr Blood Cancer ; 46(5): 637-44, 2006 May 01.
Artigo em Inglês | MEDLINE | ID: mdl-16421901

RESUMO

BACKGROUND: This study is a pilot experience aiming to investigate the compliance of an institutional cohort of Italian children treated for a malignant disease and their families in completing the health utilities index2, (HUI2) and the effectiveness of this measured in terms of their health status (HS) and health-related quality of life (HRQL). It specifically, it aimed to compare the HS and the HRQL, as expressed by the HUI2 global utility score, in cohorts of patients who had brain tumors, extra-cerebral solid tumors, or leukemia/lymphoma. PROCEDURE: Fifty survivors of brain tumors, between 8 and 30 years at the time of the assessment ("self") and/or their parents ("proxy"), attending the Pediatric Oncology Out Patient clinic of Padua, Italy, completed the HUI2 questionnaire. Eighty-nine children with acute leukemia/lymphoma and 74 with extra-cerebral solid tumors and/or their parents were also assessed. RESULTS: The mean "self" and "proxy" HUI2 global utility scores in the brain tumor patients were 0.87 and 0.84, respectively, while in the cohorts of children with other solid tumors and leukemia/lymphoma, there were 0.94, 0.91, 0.96, and 0.92, respectively. The differences between the HUI2 global utility scores in the "self" and "proxy" assessment within each cohort of children were not statistically significant. In decreasing order of frequency, the attributes affected most commonly were: "emotion," "pain," "sensation," and "cognition" both by "self" and "proxy" assessment. CONCLUSIONS: In this Italian population of childhood cancer survivors the HUI2 questionnaire proved to be a user-friendly tool, which provided information regarding HS and HRQL. A larger cohort of cancer children is needed to confirm the efficacy of the HUI2 questionnaire in distinguishing groups of children on this basis by disease category.


Assuntos
Neoplasias Encefálicas/terapia , Nível de Saúde , Qualidade de Vida , Adolescente , Adulto , Neoplasias Encefálicas/psicologia , Criança , Feminino , Humanos , Itália , Masculino , Inquéritos e Questionários , Sobreviventes
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa